Onderneming Cell Therapeutics Inc Nasdaq
Aandelen
US1509346029
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
|
2023 | Sobi rondt overname van CTI BioPharma af voor $1,7 miljard | MT |
2023 | Swedish Orphan Biovitrum rondt bod op CTI BioPharma af | MT |
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Adam Craig
CEO | Chief Executive Officer | 58 | 20-03-17 |
David Kirske
DFI | Director of Finance/CFO | 69 | 01-08-17 |
John Volpone
HRO | Human Resources Officer | - | - |
Jim Fong
PRN | Corporate Officer/Principal | 62 | 01-01-08 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Adam Craig
CEO | Chief Executive Officer | 58 | 20-03-17 |
David Parkinson
BRD | Director/Board Member | 73 | 05-06-17 |
Reed Tuckson
BRD | Director/Board Member | 73 | 01-09-11 |
Diane Parks
BRD | Director/Board Member | 71 | 24-08-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 3 047 | 0 | 0 | 95,47 % |
Aandeel B | 1 | 131 880 176 | 125 911 110 ( 95,47 %) | 0 |
Bedrijfsgegevens
CTI BioPharma Corp.
3101 Western Avenue Suite 800
98121, Seattle
+206 282 7100
http://www.ctibiopharma.com![Adres Cell Therapeutics Inc](https://cdn.zonebourse.com/static/address/8951.png)
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+38,36% | 52,5 mld. | |
+36,73% | 39,31 mld. | |
-8,63% | 39,01 mld. | |
+25,46% | 28,2 mld. | |
-11,17% | 26,57 mld. | |
+11,44% | 26,2 mld. | |
+45,09% | 14,15 mld. | |
+32,93% | 12,62 mld. | |
-5,30% | 11,74 mld. |
- Beurs
- Aandelen
- Koers CTIC
- Koers
- Onderneming Cell Therapeutics Inc